# OnCo record nct07805954 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07805954/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07805954", "NCT07805954" ;
  schema:name "Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut"@en ;
  schema:alternateName "RASolute 309"@en ;
  schema:description "A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07805954/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07805954> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-08-28" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/zoldonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:terms <https://onco.cc/terms/pancreatic-trials-open-today/>, <https://onco.cc/terms/kras-mutation-subtypes/> .